文献速递免疫规划

随机试验显示五价MenABCWY疫苗基础系列后hSBA滴度持久性达4年及加强针安全性和免疫原性

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
PubMed 文献 · Vaccine · 2024-11-08

这项在美国和欧洲开展的随机、主动对照、观察者盲法研究显示,2剂(间隔6个月)五价MenABCWY基础系列后4年内,MenA/C/W/Y血清保护率保持高位,MenB血清保护率稳定且普遍高于基线;基础免疫4年后接种加强针,5种血清群血清保护率均≥93.8%,加强针反应原性事件多为轻中度,不良事件不频繁。

要点

  • 2剂MenABCWY基础系列后4年,MenA/C/W/Y血清保护率保持高位。
  • 基础系列后4年,MenB血清保护率稳定且普遍高于基线。
  • 加强针后5种血清群血清保护率均≥93.8%,安全性可接受。

核心结论

  • MenABCWY基础系列后4年,MenA/C/W/Y免疫应答保持高位,MenB高于基线。
  • 加强针后5种血清群均观察到稳健应答,安全性和耐受性可接受,与基础系列一致。

研究设计与样本

  • 随机、主动对照、观察者盲法研究,在美国和欧洲开展。
  • 1期:10至25岁健康且未接种或曾接种MenACWY疫苗者按1:2随机接受MenABCWY加安慰剂或MenB-fHbp加MenACWY-CRM。
  • 2期:从合格参与者中随机选取进入开放标签免疫持久性和加强针扩展研究。

主要发现

  • 1379名合格参与者中353名进入2期,242名完成基础免疫后48个月采血,240名完成加强针接种阶段。
  • 基础系列后4年MenA/C/W/Y血清保护率:未接种MenACWY组62.0%-100.0%,曾接种MenACWY组98.7%-100.0%。
  • 单剂MenACWY-CRM后MenA/C/W/Y血清保护率:未接种MenACWY组38.1%-95.2%,曾接种MenACWY组89.7%-100.0%。
  • MenB血清保护率:MenABCWY组18.2%-36.6%,MenB-fHbp组16.2%-31.9%(跨菌株)。
  • 加强针后所有组针对5种血清群的血清保护率均≥93.8%。

关键数值与推荐

  • 免疫原性终点包括基础免疫后至48个月及加强针后1个月的hSBA血清保护率。
  • 安全性终点包括加强针反应原性事件和不良事件(AEs)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination against 5 prominent meningococcal serogroups (A/B/C/W/Y) is necessary for broad disease protection. We report immunopersistence through 4 years after a 2-dose (6-month interval) pentavalent MenABCWY primary vaccine series and safety and immunogenicity of a booster administered 4 years after primary vaccination. METHODS: This randomized, active-controlled, observer-blinded study was conducted in the United States and Europe. In stage 1, healthy MenACWY vaccine-naive or -experienced 10- to 25-year-olds were randomized 1:2 to receive MenABCWY and placebo or MenB-fHbp and MenACWY-CRM. Eligible participants were randomly selected to participate in stage 2, which was an open-label immunopersistence and booster extension. Immunogenicity was assessed through serum bactericidal antibody using human complement (hSBA) assays with serogroups A/C/W/Y (MenA/C/W/Y) and 4 primary serogroup B (MenB) test strains. Immunogenicity endpoints included hSBA seroprotection rates through 48 months after primary vaccination and 1 month after the booster. Safety endpoints included booster reactogenicity events and adverse events (AEs). RESULTS: Of 1379 eligible participants, 353 entered stage 2; 242 completed the 48-month blood draw after primary vaccination and 240 completed the booster vaccination phase. MenA/C/W/Y seroprotection rates remained high for 4 years following a 2-dose MenABCWY primary series (MenACWY-naive, 62.0 %-100.0 %; MenACWY-experienced, 98.7 %-100.0 %) and trended higher than those after a single MenACWY-CRM dose (MenACWY-naive, 38.1 %-95.2 %; MenACWY-experienced, 89.7 %-100.0 %). Corresponding seroprotection rates against MenB remained stable and generally higher than baseline (MenABCWY, 18.2 %-36.6 %; MenB-fHbp, 16.2 %-31.9 % across strains). Following a booster, seroprotection rates against all 5 serogroups were ≥ 93.8 % across groups. Most booster dose reactogenicity events were mild or moderate in severity, and AEs were infrequent. CONCLUSIONS: Immune responses remained high for MenA/C/W/Y and above baseline for MenB through 4 years after the MenABCWY primary series, with robust responses for all 5 serogroups observed following a booster. The MenABCWY booster had an acceptable safety and tolerability profile consistent with the primary series. NCT03135834.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Peterson J, Drazan D, Moughan B, et al. Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose. Vaccine. 2024. PMID: 39520893. doi:10.1016/j.vaccine.2024.126469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。